milnacipran + pindolol

Milnacipran + pindolol is a combination of two small molecule drugs used experimentally in the treatment of major depressive disorder. Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) that increases extracellular levels of both neurotransmitters by blocking their reuptake, leading to antidepressant and analgesic effects. Pindolol is a nonselective beta-adrenergic receptor blocker with additional antagonism at 5-HT1A receptors; it has been used to augment antidepressant response, particularly by accelerating the onset of action when combined with serotonergic agents. The rationale for this combination lies in evidence that pindolol potentiates the effect of milnacipran on noradrenaline and serotonin systems, likely through antagonism of presynaptic 5-HT1A autoreceptors, thereby enhancing neurotransmitter release. This strategy has shown efficacy and good tolerability in clinical trials for major depression[1][3].